Background: Limited evidence exists regarding adverse modifications affecting cardiovascular and pulmonary function in physical active adults affected by COVID-19, especially in athletic populations. We aimed to describe the clinical presentation of COVID-19 in a cohort of competitive athletes, as well as spirometry and echocardiography findings and cardio-respiratory performance during exercise. Methods: Twenty-four competitive athletes with COVID-19 were recruited for this study after ending self-isolation and confirmation of negative laboratory results. All athletes underwent clinical evaluation, spirometry, echocardiography and cardiopulmonary exercise testing (CPET). These data were compared to a group of healthy control athletes. Results: Anosmia was the most frequent symptom present in 70.83% patients, followed by myalgia, fatigue and ageusia. The most frequent persisting symptoms were anosmia 11 (45.83%) and ageusia 8 (33.33%). Compared to controls, COVID-19 patients presented lower FEV1%: 97.5 (91.5–108) vs. 109 (106–116) p = 0.007. Peak Oxygen Uptake (VO 2 ) in COVID-19 patients was 50.1 (47.7–51.65) vs. 49 (44.2–52.6) in controls ( p = 0.618). Conclusions: Reduced exercise capacity was not identified and pulmonary and cardiovascular function are not impaired during early recovery phase in a population of physical active adults except FEV1 reduction.
【저자키워드】 COVID-19, Physical exercise, CPET, SARS-COV-19, 【초록키워드】 fatigue, Exercise capacity, spirometry, Symptom, Anosmia, Cohort, Cardiovascular function, Pulmonary function, Laboratory results, Ageusia, cardiopulmonary exercise testing, clinical evaluation, Control, uptake, patients, Evidence, COVID-19 patient, myalgia, early recovery, Self-isolation, reduction, healthy control, Modification, populations, peak, controls, physical, affected, recruited, affecting, athletic, Limited, with COVID-19, 【제목키워드】 exercise, pulmonary, clinical, Capacity, function, athlete,